Eight-year survival of a recurrent glioblastoma patient treated with molecularly tailored therapy: a case report

Quintino Giorgio D’Alessandris, Nicola Montano, Maurizio Martini, Tonia Cenci, Liverana Lauretti, Vittorio Stumpo, Fabrizio Pignotti, Alessandro Olivi, Eduardo Fernandez, Luigi Maria Larocca, Roberto Pallini

Research output: Contribution to journalArticle

Abstract

Treatment options for recurrent glioblastoma are scarce; targeted therapy trials were disappointing, probably due to enrollment of patients without molecular selection. We treated with bevacizumab and erlotinib a 66-year-old male suffering from recurrent glioblastoma, IDH-wildtype and MGMT unmethylated, after three neurosurgeries. Treatment was tailored on molecular profile of recurrent tumor—namely, EGFRvIII positivity, VEGF overexpression, normal PTEN, low total VEGF and VEGF-121 mRNA—and resulted in complete, exceptionally durable response (51-month progression-free survival). Notably, histology of further recurrence after therapy was reminiscent of sarcoma. We suggest a thorough molecular screening for personalization of targeted therapy in recurrent glioblastoma.

Original languageEnglish (US)
JournalActa Neurochirurgica
DOIs
StateAccepted/In press - Jan 1 2018
Externally publishedYes

Fingerprint

Glioblastoma
Survival
Vascular Endothelial Growth Factor A
Therapeutics
Neurosurgery
Psychological Stress
Sarcoma
Disease-Free Survival
Histology
Recurrence

Keywords

  • Bevacizumab
  • Erlotinib
  • Glioblastoma
  • Tailored therapy
  • Targeted therapy

ASJC Scopus subject areas

  • Surgery
  • Clinical Neurology

Cite this

D’Alessandris, Q. G., Montano, N., Martini, M., Cenci, T., Lauretti, L., Stumpo, V., ... Pallini, R. (Accepted/In press). Eight-year survival of a recurrent glioblastoma patient treated with molecularly tailored therapy: a case report. Acta Neurochirurgica. https://doi.org/10.1007/s00701-018-3697-3

Eight-year survival of a recurrent glioblastoma patient treated with molecularly tailored therapy : a case report. / D’Alessandris, Quintino Giorgio; Montano, Nicola; Martini, Maurizio; Cenci, Tonia; Lauretti, Liverana; Stumpo, Vittorio; Pignotti, Fabrizio; Olivi, Alessandro; Fernandez, Eduardo; Larocca, Luigi Maria; Pallini, Roberto.

In: Acta Neurochirurgica, 01.01.2018.

Research output: Contribution to journalArticle

D’Alessandris, QG, Montano, N, Martini, M, Cenci, T, Lauretti, L, Stumpo, V, Pignotti, F, Olivi, A, Fernandez, E, Larocca, LM & Pallini, R 2018, 'Eight-year survival of a recurrent glioblastoma patient treated with molecularly tailored therapy: a case report', Acta Neurochirurgica. https://doi.org/10.1007/s00701-018-3697-3
D’Alessandris, Quintino Giorgio ; Montano, Nicola ; Martini, Maurizio ; Cenci, Tonia ; Lauretti, Liverana ; Stumpo, Vittorio ; Pignotti, Fabrizio ; Olivi, Alessandro ; Fernandez, Eduardo ; Larocca, Luigi Maria ; Pallini, Roberto. / Eight-year survival of a recurrent glioblastoma patient treated with molecularly tailored therapy : a case report. In: Acta Neurochirurgica. 2018.
@article{8098cdc018a64e0c955f2742fd4e46ad,
title = "Eight-year survival of a recurrent glioblastoma patient treated with molecularly tailored therapy: a case report",
abstract = "Treatment options for recurrent glioblastoma are scarce; targeted therapy trials were disappointing, probably due to enrollment of patients without molecular selection. We treated with bevacizumab and erlotinib a 66-year-old male suffering from recurrent glioblastoma, IDH-wildtype and MGMT unmethylated, after three neurosurgeries. Treatment was tailored on molecular profile of recurrent tumor—namely, EGFRvIII positivity, VEGF overexpression, normal PTEN, low total VEGF and VEGF-121 mRNA—and resulted in complete, exceptionally durable response (51-month progression-free survival). Notably, histology of further recurrence after therapy was reminiscent of sarcoma. We suggest a thorough molecular screening for personalization of targeted therapy in recurrent glioblastoma.",
keywords = "Bevacizumab, Erlotinib, Glioblastoma, Tailored therapy, Targeted therapy",
author = "D’Alessandris, {Quintino Giorgio} and Nicola Montano and Maurizio Martini and Tonia Cenci and Liverana Lauretti and Vittorio Stumpo and Fabrizio Pignotti and Alessandro Olivi and Eduardo Fernandez and Larocca, {Luigi Maria} and Roberto Pallini",
year = "2018",
month = "1",
day = "1",
doi = "10.1007/s00701-018-3697-3",
language = "English (US)",
journal = "Acta Neurochirurgica",
issn = "0001-6268",
publisher = "Springer Wien",

}

TY - JOUR

T1 - Eight-year survival of a recurrent glioblastoma patient treated with molecularly tailored therapy

T2 - a case report

AU - D’Alessandris, Quintino Giorgio

AU - Montano, Nicola

AU - Martini, Maurizio

AU - Cenci, Tonia

AU - Lauretti, Liverana

AU - Stumpo, Vittorio

AU - Pignotti, Fabrizio

AU - Olivi, Alessandro

AU - Fernandez, Eduardo

AU - Larocca, Luigi Maria

AU - Pallini, Roberto

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Treatment options for recurrent glioblastoma are scarce; targeted therapy trials were disappointing, probably due to enrollment of patients without molecular selection. We treated with bevacizumab and erlotinib a 66-year-old male suffering from recurrent glioblastoma, IDH-wildtype and MGMT unmethylated, after three neurosurgeries. Treatment was tailored on molecular profile of recurrent tumor—namely, EGFRvIII positivity, VEGF overexpression, normal PTEN, low total VEGF and VEGF-121 mRNA—and resulted in complete, exceptionally durable response (51-month progression-free survival). Notably, histology of further recurrence after therapy was reminiscent of sarcoma. We suggest a thorough molecular screening for personalization of targeted therapy in recurrent glioblastoma.

AB - Treatment options for recurrent glioblastoma are scarce; targeted therapy trials were disappointing, probably due to enrollment of patients without molecular selection. We treated with bevacizumab and erlotinib a 66-year-old male suffering from recurrent glioblastoma, IDH-wildtype and MGMT unmethylated, after three neurosurgeries. Treatment was tailored on molecular profile of recurrent tumor—namely, EGFRvIII positivity, VEGF overexpression, normal PTEN, low total VEGF and VEGF-121 mRNA—and resulted in complete, exceptionally durable response (51-month progression-free survival). Notably, histology of further recurrence after therapy was reminiscent of sarcoma. We suggest a thorough molecular screening for personalization of targeted therapy in recurrent glioblastoma.

KW - Bevacizumab

KW - Erlotinib

KW - Glioblastoma

KW - Tailored therapy

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=85055184229&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055184229&partnerID=8YFLogxK

U2 - 10.1007/s00701-018-3697-3

DO - 10.1007/s00701-018-3697-3

M3 - Article

C2 - 30306271

AN - SCOPUS:85055184229

JO - Acta Neurochirurgica

JF - Acta Neurochirurgica

SN - 0001-6268

ER -